Furthermore, the pharmacological use of FGF-21 analogues has been proposed in the treatment of dyslipidemia, obesity, type 2 diabetes, and NASH (21–23). This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.